Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5980 Horton Street, Suite 600 EMERYVILLE CA 94608 |
Tel: | N/A |
Website: | https://www.omniab.com |
IR: | See website |
Key People | ||
John L. Higgins Chairman of the Board | Matthew William Foehr President, Chief Executive Officer, Director | Kurt A. Gustafson Chief Financial Officer, Executive Vice President - Finance | Charles Stuart Berkman Chief Legal Officer, Secretary |
Business Overview |
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens. |
Financial Overview |
For the fiscal year ended 31 December 2023, OmniAB Inc revenues decreased 42% to $34.2M. Net loss increased from $22.3M to $50.6M. Revenues reflect License and milestone revenue segment decrease of 47% to $20.7M, Service revenue segment decrease of 35% to $12.2M. Higher net loss reflects Research and development - Balancing val increase of 15% to $43.7M (expense). |
Employees: | 106 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $461.26M as of Mar 31, 2024 |
Annual revenue (TTM): | $34.16M as of Mar 31, 2024 |
EBITDA (TTM): | -$49.92M as of Mar 31, 2024 |
Net annual income (TTM): | -$50.62M as of Mar 31, 2024 |
Free cash flow (TTM): | $0.70M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 117,145,176 as of Mar 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |